Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago. These ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sutro Biopharma (STRO – Research Report) and ...

Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...

PharmaCord has about 1,100 employees, while Mercalis has about 1,800 with a high percentage of its employees based in the ...

As of December 31, 2024, Sutro had cash, cash equivalents and marketable securities of $316.9 million, as compared to $388.3 million as of September 30, 2024. Cash runway is expected into at least Q4 ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well in a declining market. AstraZeneca stock is nearing a buy point after ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Arizona State Retirement System raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.9% during ...

Analysts at Needham & Company LLC initiated coverage on shares of Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) in a ...